Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects

Byron J. Hoogwerf; John P. Bantle; Heidi E. Gaenslen; Beryl Z. Greenberg; Beverly J. Senske; Reynold Francis; Frederick C. Goetz

doi:10.1016/0026-0495(86)90111-3

Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects

Byron J. Hoogwerf, John P. Bantle, Heidi E. Gaenslen, Beryl Z. Greenberg, Beverly J. Senske, Reynold Francis, Frederick C. Goetz

Medicine - Endocrine and Diabetes Division

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

We studied six healthy male subjects to determine whether a four-hour infusion of synthetic human C-peptide sufficient to achieve mean (±SD) peripheral plasma concentrations of 1.3 ± 0.7 pmol/mL affected plasma glucose, serum insulin, or plasma glucagon. Subjects were studied in a fasting state and following an oral glucose load during four-hour 0.9% NaCl (control) and C-peptide (mean dose: 70 nmol) infusions. No differences were observed between saline and C-peptide infusions for mean values of fasting plasma glucose (94 ± 6 v 87 ± 5 mg/dL), serum insulin (3 ± 1 v 2 ± 1 μU/mL), or plasma glucagon (124 ± 65 v 112 ± 70 pg/dL). Following oral glucose ingestion no differences were detected between saline and C-peptide infusions for mean peak values of plasma glucose (168 ± 18 v 168 ± 31) and serum insulin (59 ± 6 v 57 ± 21) or mean nadir values of plasma glucagon (80 ± 73 v 75 ± 70). There was a slight delay in the insulin rise following oral glucose on the C-peptide infusion day, but differences between mean values for individual sampling times were not statistically significantly different.

Original language	English (US)
Pages (from-to)	122-125
Number of pages	4
Journal	Metabolism
Volume	35
Issue number	2
DOIs	https://doi.org/10.1016/0026-0495(86)90111-3
State	Published - Feb 1986

Bibliographical note

Funding Information:
From the Department of Medicine, Division of Endocrinology and Metabolism and the General Clinical Research Center, University of Minnesota, Minneapolis. Supported by the General Clinical Research Center Branch of the Division of Research Resources, NIH (RR 400). The Eli Lilly Company (Indianapolis, Indiana), and The American Diabetes Association, Minnesota Afiliate. Dr Hoogwerf is the recipient of a Special Emphasis Research Career Award (IKOI AG00151) in Diabetes and Aging from The National Institute on Aging. Address reprint requests to Dr Byron J. Hoogwerf. Department of Endocrinology. Cleveland Clinic Foundation, Cleveland, OH 44106. o 1986 by Grune & Stratton, Inc. 0026-0495/86/3502-0006$03.00/0

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/0026-0495(86)90111-3

OpenUrl availability

Full text

Cite this

@article{fc96a1480a834caf8a571eb3f5812e76,

title = "Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects",

abstract = "We studied six healthy male subjects to determine whether a four-hour infusion of synthetic human C-peptide sufficient to achieve mean (±SD) peripheral plasma concentrations of 1.3 ± 0.7 pmol/mL affected plasma glucose, serum insulin, or plasma glucagon. Subjects were studied in a fasting state and following an oral glucose load during four-hour 0.9% NaCl (control) and C-peptide (mean dose: 70 nmol) infusions. No differences were observed between saline and C-peptide infusions for mean values of fasting plasma glucose (94 ± 6 v 87 ± 5 mg/dL), serum insulin (3 ± 1 v 2 ± 1 μU/mL), or plasma glucagon (124 ± 65 v 112 ± 70 pg/dL). Following oral glucose ingestion no differences were detected between saline and C-peptide infusions for mean peak values of plasma glucose (168 ± 18 v 168 ± 31) and serum insulin (59 ± 6 v 57 ± 21) or mean nadir values of plasma glucagon (80 ± 73 v 75 ± 70). There was a slight delay in the insulin rise following oral glucose on the C-peptide infusion day, but differences between mean values for individual sampling times were not statistically significantly different.",

author = "Hoogwerf, {Byron J.} and Bantle, {John P.} and Gaenslen, {Heidi E.} and Greenberg, {Beryl Z.} and Senske, {Beverly J.} and Reynold Francis and Goetz, {Frederick C.}",

note = "Funding Information: From the Department of Medicine, Division of Endocrinology and Metabolism and the General Clinical Research Center, University of Minnesota, Minneapolis. Supported by the General Clinical Research Center Branch of the Division of Research Resources, NIH (RR 400). The Eli Lilly Company (Indianapolis, Indiana), and The American Diabetes Association, Minnesota Afiliate. Dr Hoogwerf is the recipient of a Special Emphasis Research Career Award (IKOI AG00151) in Diabetes and Aging from The National Institute on Aging. Address reprint requests to Dr Byron J. Hoogwerf. Department of Endocrinology. Cleveland Clinic Foundation, Cleveland, OH 44106. o 1986 by Grune & Stratton, Inc. 0026-0495/86/3502-0006$03.00/0",

year = "1986",

month = feb,

doi = "10.1016/0026-0495(86)90111-3",

language = "English (US)",

volume = "35",

pages = "122--125",

journal = "Metabolism",

issn = "0026-0495",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects

AU - Hoogwerf, Byron J.

AU - Bantle, John P.

AU - Gaenslen, Heidi E.

AU - Greenberg, Beryl Z.

AU - Senske, Beverly J.

AU - Francis, Reynold

AU - Goetz, Frederick C.

N1 - Funding Information: From the Department of Medicine, Division of Endocrinology and Metabolism and the General Clinical Research Center, University of Minnesota, Minneapolis. Supported by the General Clinical Research Center Branch of the Division of Research Resources, NIH (RR 400). The Eli Lilly Company (Indianapolis, Indiana), and The American Diabetes Association, Minnesota Afiliate. Dr Hoogwerf is the recipient of a Special Emphasis Research Career Award (IKOI AG00151) in Diabetes and Aging from The National Institute on Aging. Address reprint requests to Dr Byron J. Hoogwerf. Department of Endocrinology. Cleveland Clinic Foundation, Cleveland, OH 44106. o 1986 by Grune & Stratton, Inc. 0026-0495/86/3502-0006$03.00/0

PY - 1986/2

Y1 - 1986/2

N2 - We studied six healthy male subjects to determine whether a four-hour infusion of synthetic human C-peptide sufficient to achieve mean (±SD) peripheral plasma concentrations of 1.3 ± 0.7 pmol/mL affected plasma glucose, serum insulin, or plasma glucagon. Subjects were studied in a fasting state and following an oral glucose load during four-hour 0.9% NaCl (control) and C-peptide (mean dose: 70 nmol) infusions. No differences were observed between saline and C-peptide infusions for mean values of fasting plasma glucose (94 ± 6 v 87 ± 5 mg/dL), serum insulin (3 ± 1 v 2 ± 1 μU/mL), or plasma glucagon (124 ± 65 v 112 ± 70 pg/dL). Following oral glucose ingestion no differences were detected between saline and C-peptide infusions for mean peak values of plasma glucose (168 ± 18 v 168 ± 31) and serum insulin (59 ± 6 v 57 ± 21) or mean nadir values of plasma glucagon (80 ± 73 v 75 ± 70). There was a slight delay in the insulin rise following oral glucose on the C-peptide infusion day, but differences between mean values for individual sampling times were not statistically significantly different.

AB - We studied six healthy male subjects to determine whether a four-hour infusion of synthetic human C-peptide sufficient to achieve mean (±SD) peripheral plasma concentrations of 1.3 ± 0.7 pmol/mL affected plasma glucose, serum insulin, or plasma glucagon. Subjects were studied in a fasting state and following an oral glucose load during four-hour 0.9% NaCl (control) and C-peptide (mean dose: 70 nmol) infusions. No differences were observed between saline and C-peptide infusions for mean values of fasting plasma glucose (94 ± 6 v 87 ± 5 mg/dL), serum insulin (3 ± 1 v 2 ± 1 μU/mL), or plasma glucagon (124 ± 65 v 112 ± 70 pg/dL). Following oral glucose ingestion no differences were detected between saline and C-peptide infusions for mean peak values of plasma glucose (168 ± 18 v 168 ± 31) and serum insulin (59 ± 6 v 57 ± 21) or mean nadir values of plasma glucagon (80 ± 73 v 75 ± 70). There was a slight delay in the insulin rise following oral glucose on the C-peptide infusion day, but differences between mean values for individual sampling times were not statistically significantly different.

UR - http://www.scopus.com/inward/record.url?scp=0022602308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022602308&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(86)90111-3

DO - 10.1016/0026-0495(86)90111-3

M3 - Article

C2 - 3511350

AN - SCOPUS:0022602308

SN - 0026-0495

VL - 35

SP - 122

EP - 125

JO - Metabolism

JF - Metabolism

IS - 2

ER -

Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this